Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at AACR 2022
Shots:
- The P-III (JUPITER-02) study evaluate Toripalimab (240mg) + CT vs CT + PBO in a ratio (1:1) in 289 patients with NPC
- In the final PFS analysis, toripalimab + CT showed an improvement in PFS with m-PFS (21.4mos. vs 8.2mos.), improvements in the 2EPs of PFS, ORR (78.8% vs 67.1%), DoR (18.0mos. vs 6.0mos.), m-OS not yet mature, 41% reduction in risk of death. The safety profile was consistent with previously reported in other toripalimab with no new safety signals
- The interim OS analysis showed a trend favors toripalimab arm & will be formally tested in a prespecified final analysis. The combination therapy has received BTD as 1L treatment & toripalimab monothx. as a 2L treatment for the same indication
Ref: Globenewswire| Image: Coherus
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
